Timeframe: 2019 – 2022 Goal: Investigate the potential of AURKA inhibitors for FLC treatment Principal Investigator: John Gordan, MD, PhD, Assistant Professor, Department of Medicine, UCSF Co-Investigator: Nabeel Bardeesy, Associate Professor, Massachusetts General Hospital, Harvard University Even though the DNAJB1-PRKACA gene fusion (encoding a chimeric protein with a domain of heat shock protein 40, HSP40, …
Timeframe: 2021 – 2022 Investigators: John Gordan, MD, PhD, Assistant Professor, Department of Medicine, UCSF; Travis Zack, MD, UCSF; and Kurt Losert, FCF Goal: Develop updated estimate for US national incidence of FLC The most cited study of national incidence of FLC, using data from the National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER) …
Timeframe: 2016 – 2019 Goal: Understand growth mechanisms and identify potential therapeutic targets Principal Investigators: John Gordan. M.D., Ph.D, Clinical Instructor, University of California San Francisco; Nabeel Bardeesy, Ph.D, Associate Professor, Harvard University The discovery of a genetic change in the protein kinase A (PKA) gene in nearly all cases of fibrolamellar liver cancer (FLC) …
Timeframe: 2016 – 2019 Goal: Study the interactions between the immune system and FLC in a mouse model Principal Investigator: Kevin Barry, Ph.D., Postdoctoral Scholar Cancer immunotherapies harness the power of the immune system to kill tumors. Checkpoint blockade immunotherapies are an exciting class of cancer immunotherapies that remove the brakes from the immune system …